SIRT1 and metabolic dysfunction-associated steatotic liver disease: In clinical investigations, the implication of resveratrol and GLP-1 (Glucagon-like peptide-1) receptor agonists, both of which can activate SIRT1, in NAFLD treatment has been investigated.